# S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

> **NCT00033540** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 57 (actual)

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00033540
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2008-04
- **Final completion:** 2011-07
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2017-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00033540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00033540, "S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00033540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*